Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Biopharma save search
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
KRBP | $2.71 2.65% -90.21% 0
|
Health Technology
|
| O: 0.0%
H: 11.74%
C: 2.65%
first favorable biopharma trial
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | $0.81 -0.11% 0.38% 24K
|
n/a
|
| O: -7.45%
H: 0.0%
C: 0.0%
hepatitis vaccine license granted biopharma virus trial
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.72 -2.04% -1.63% 67K
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Published: 2024-04-02 (Crawled : 16:00) - biospace.com/
KRBP | $2.71 2.65% -90.21% 0
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.0%
favorable biopharma trial
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Published: 2024-03-20 (Crawled : 13:30) - globenewswire.com
IMMX | $2.13 -7.39% -6.98% 14
|
|
| O: -2.9%
H: 10.07%
C: 2.24%
nxc-201 cancer biopharma trial
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
Published: 2024-03-01 (Crawled : 13:30) - biospace.com/
KRBP | $2.71 2.65% -90.21% 0
|
Health Technology
|
| O: -4.03%
H: 0.0%
C: -5.6%
biopharma ongoing trial
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Published: 2024-02-20 (Crawled : 12:30) - globenewswire.com
MTNB | $0.1818 0.17% 2.04% 520K
|
Health Technology
|
| O: 4.35%
H: 11.21%
C: -0.46%
mat2203 fda treatment biopharma trial agreement
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
Published: 2024-01-29 (Crawled : 15:00) - biospace.com/
KRBP | $2.71 2.65% -90.21% 0
|
Health Technology
|
| O: -6.67%
H: 27.14%
C: 26.43%
first lung favorable cancer cell biopharma trial results
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
Published: 2024-01-05 (Crawled : 14:30) - biospace.com/
KRBP | $2.71 2.65% -90.21% 0
|
Health Technology
|
| O: 15.5%
H: 12.55%
C: 3.9%
first favorable biopharma trial
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-12-18 (Crawled : 12:30) - globenewswire.com
PNT | $13.68 2.63% 0.15% 0
|
|
| O: -10.09%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
|
| O: 1.61%
H: 1.14%
C: 0.57%
LNTH | $65.21 1.24% 1.2% 580K
|
Health Technology
|
| O: -19.87%
H: 5.04%
C: -8.75%
positive cancer biopharma topline trial results
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
Published: 2023-12-11 (Crawled : 21:00) - globenewswire.com
CNTB | $1.37 -1.44% 3.57% 41K
|
Professional, Scientific, and T...
|
| O: -8.59%
H: 5.75%
C: -0.57%
biopharma global trial
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials
Published: 2023-12-05 (Crawled : 13:30) - globenewswire.com
ABVC | $1.48 9.63% 8.47% 97K
|
Wholesale Trade
|
| O: 5.07%
H: 1.38%
C: -0.69%
irwin cancer depression biopharma trials medical
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
BNTC | $6.72 -2.04% -1.63% 67K
|
Health Technology
|
| O: 4.58%
H: 8.29%
C: -0.63%
bb-301 candidate treatment biopharma trial therapy
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
Published: 2023-11-21 (Crawled : 11:00) - globenewswire.com
CNTB | $1.37 -1.44% 3.57% 41K
|
Professional, Scientific, and T...
|
| O: 6.31%
H: 2.28%
C: -42.47%
dermatitis positive biopharma trial china
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
Published: 2023-11-20 (Crawled : 22:00) - globenewswire.com
CNTB | $1.37 -1.44% 3.57% 41K
|
Professional, Scientific, and T...
|
| O: 6.31%
H: 2.28%
C: -42.47%
dermatitis biopharma trial china
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
ABUS | $2.75 -0.36% 160
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -3.28%
vtp-300 meeting liver biopharma trial
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
ABUS | $2.75 -0.36% 160
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -3.28%
hbv003 biopharma collaboration trial
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
Published: 2023-11-09 (Crawled : 13:30) - biospace.com/
KRBP | $2.71 2.65% -90.21% 0
|
Health Technology
|
| O: 3.96%
H: 53.85%
C: 53.85%
cancer biopharma trial
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 1.5K
|
Health Technology
|
| O: 1.35%
H: 16.44%
C: 8.89%
cue-101 positive cue cancer biopharma tumor cue-102 trials
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
Published: 2023-10-31 (Crawled : 15:00) - biospace.com/
YS | $0.81 -0.11% 0.38% 24K
|
n/a
|
| O: 12.03%
H: 3.3%
C: -12.0%
vaccine biopharma trial
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
IHT P | $1.3712 0.82% 6.48% 0
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.